Emerging drug therapies for benign prostatic hyperplasia (Q34565171)

3 August 2017

1 reference

title

Emerging drug therapies for benign prostatic hyperplasia (English)

1 reference

3 August 2017

Travis L Bullock

1

1 reference

3 August 2017

Gerald L Andriole

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Emerging Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

111-123

1 reference

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Alfuzosin: a clinically uroselective alpha1-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The efficacy and safety of a new once-a-day formulation of an alpha-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.1.111

10.1517/14728214.11.1.111

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference